Direct-acting Oral Anticoagulants: An Overview

Area of Science:

• Pharmacology
• Cardiology
• Hematology

Background:

• Anticoagulant therapy is increasingly prescribed for thrombosis prophylaxis and treatment.
• Non-Vitamin K antagonists (NOACs) have been introduced as alternatives to traditional anticoagulants.
• NOACs are widely used for atrial fibrillation and venous thromboembolism due to efficacy and safety.

Purpose of the Study:

• To evaluate the efficacy and safety of novel anticoagulants compared to standard treatments.
• To highlight the advantages of NOACs, including rapid onset and reduced monitoring.
• To emphasize the importance of considering renal function and specific indications for NOAC use.

Main Methods:

• Comparative analysis of NOACs against low-molecular-weight heparin and warfarin.
• Review of clinical data on efficacy, safety, and adverse events.
• Assessment of NOACs' pharmacokinetic and pharmacodynamic profiles.

Main Results:

• NOACs demonstrate comparable efficacy and safety to traditional anticoagulants.
• NOACs offer convenience with rapid onset and no routine monitoring requirements.
• NOACs show a lower incidence of intracranial bleeding compared to warfarin.

Conclusions:

• NOACs are effective and safe alternatives for many anticoagulant indications.
• Clinicians must monitor renal function and adhere to approved dosages and indications.
• Warfarin remains the preferred agent for specific conditions like prosthetic valves and antiphospholipid syndrome.